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Clinical Practice Guidelines (CPGs) are documents used in daily clini-
cal practice that provide advice on how to best diagnose and treat diseases
in the form of a list of clinical recommendations. When simultaneously ap-
plying multiple CPGs to patients, this can lead to complex multiple drug
regimens (polypharmacy) with the potential for harmful combinations of
drugs. The need to address these adverse drug events calls forth for sys-
tems capable of not only automatically represent the common potential
conflicts or interactions that can happen when merging CPGs but also sys-
tems capable of providing conflict-free alternatives. This paper presents
a solution that represents CPGs as Computer-Interpretable Guidelines
(CIGs) and allows the automatic identification of drug conflicts and the
provision of alternative measures to resolve these conflicts.
1 Introduction
Drug-drug interactions occur when an effect of one drug alters the effect of
another co-administrated drug [6]. Such interactions are common in multimorbid
patients since they suffer multiple health conditions and need the application
of different disease-specific treatment plans. To help ease the burden of health
care professionals, Clinical Practice Guidelines (CPGs) were developed in order
to provide patient-specific advice. These documents accumulate and reflect
knowledge on how to best diagnose and treat diseases in the form of a list
of clinical recommendations. When treating multimorbid patients, health care
professionals need to retrieve clinical recommendations from multiple chronic
disease CPGs. The result is concurrent execution of treatment recommendations
from different CPGs, which may cause conflicts. From the combination of these
recommendations, several problems can happen, such includes adverse drug
events, and increased treatment complexity and cost of treatment [2].
Several projects were developed not only to formally represent CPGs as
Computer Interpretable-Guidelines (CIGs). Through the formalisation of CPGs
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as CIGs it is possible to develop decision support systems that offer a better
possibility of affecting clinical behaviour in relation to narrative documents of
the corresponding text versions. The representation of CPGs in digital for-
mat can have distinct benefits over paper-based CPGs in that they increase
flexibility, minimise errors, and generalise the use of CPGs across institutions.
However, few works address potential conflicts or interactions that can happen
when merging CIGs.
Although some approaches offer ways to represent the conflicts and interac-
tions between concurrent CIGs, they lack in: provision of alternative measures
to resolve conflicts in treatment plans, dynamic search for solutions to conflicts
outside the existing knowledge base, and provision of methods to rank and select
treatment plans. The first contribution of this work is a characterisation of ex-
isting approaches to handle the combination of CIGs, especially for multimorbid
patients. Then, it presents a system that automatically identifies recommen-
dation interactions, conflicts, and provides alternative measures (mainly in the
form of alternative drug recommendations) that resolve the identified conflicts.
The paper is organised as follows. Section 2 describes related work regarding
systems for combining CIGs. Section 3, presents an architecture for combining
CIGs as well as the contributions for the deployment of CIGs in Clinical Decision
Support Systems (CDSSs). Section 4 describes the functionalities supporting
care with a case example of how the system processes drug-drug interactions
and provides alternative measures. Finally, Section 5 presents conclusions about
the work developed so far and future work considerations.
2 Related Work
Several formalisms are proposed in the literature that are aimed to represent the
conflicts and interactions among different CPGs. They provide various methods
to model the conflicts of CPGs into their knowledge base. In this section, we
describe different systems that automatically identify the possible interactions
between concurrent CPGs for multimorbid patients.
Wilk et al. [13] represent CIGs as an activity graph. They use constraint
logic programming and combines it with constraint satisfaction problems. By
using constraint logic programming, they identify and mitigate possible adverse
interactions when applying multiple guidelines on the same patient, namely
identifying conflicts associated with potentially contradictory and adverse activ-
ities. They provide notification features that inform the healthcare professionals
about the possible conflicts during the definition of the treatment plans. This
approach provides automatic identification of conflicts, however, it depends on
the availability of the information in the knowledge base about the conflicts
between both CIGs in the form of constraints and of pre-existing operators to
mitigate these conflicts. This requires substantial manual effort for combin-
ing CIGs. Thus, in order to provide automatic identification and resolution
of conflicts, solutions need to be defined in a medical background knowledge as
protocol-dependent rules/constraints.
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Lopez et al. [8] used a rule-based methodology in order to identify and
reconcile drug conflicts between recommendations of two concurrently executed
CIGs. In order to provide a treatment plan without interactions, they utilise
a standard terminology called ATC (Anatomical Therapeutic Chemical Clas-
sification System for drugs). The outputted treatment plan comprises a set
of ATC-codes of medicines, without interactions, which should be prescribed.
They manually build knowledge units for the pairwise combination of diseases in
their knowledge base. These knowledge units rely on the existence of drug-drug
interactions, the presence of a drug which is adverse to a specific disease (drug-
disease interaction) and the absence of a necessary medicine for a combination
of diseases. Although this approach can only combine CPGs pairwise, it is pos-
sible to achieve a final treatment plan for any number of CIGs by combining a
pair of CIGs into a general CIG and then combining the latter with a new CIG.
This approach requires significant manual effort as each combination has to be
hardcoded.
OntoMorph [5] represent guidelines as a collection of ontologies. They use
information such as the general domain, the mappings between CPGs and de-
cision rules for simultaneous execution of CPGs that are provided by domain
experts. Based on these ontologies, they developed a system capable of merging
two concurrent CIGs into a co-morbid personalised guideline. By representing
the CIGs as ontologies, it allows retrieving the clinical tasks from the CPG
and converts them to computer-interpretable rules in Ontology Web Language
(OWL). Using ontologies is one of the possible solutions to CPG representa-
tion. It allows the representation of declarative knowledge (medical statements
and propositions) and procedural knowledge (workflow structures and actions)
as rules. Ontomorph also has a merging representation ontology, which allows
capturing merging criteria to achieve the combination of CIGs. By using Se-
mantic Web Rule Language(SWRL) rules, they can identify potential conflicts
during the merging process. Since all conditions need to be defined in their
model during the merging process, this increases the effort to maintain the
system up-to-date and reduces the possibility of sharing knowledge. In their
work, some of the identified limitations were not yet entirely addressed, such as
potential contradictions between rules, the scalability of the merging model to
combine several CIGs, and how the ontology/rules are maintained up-to-date.
The Transition-based Medical Recommendations for Interactions (TMR4I)
model is a model that automatically infers the interaction between recommen-
dations [14] by using meta-rules for the identification and reconciliation of three
categories of drug conflicts using SPARQL queries (SPARQL is a W3C-standard
for semantic queries). Using meta-rules allows defining how a conflict is identi-
fied and how similar drugs without interactions and conflicts can be selected as
alternatives. The categories of conflicts within CPGs are repetition interactions,
contradiction interactions and alternative interactions. The model was extend
in [14] with additional interaction types and several measures such as deontic
strength, causation belief, and belief strength. This work provides only a rep-
resentation of conflicts but does not afford reasoning or any form of decision
support.
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The limitations of above-mentioned approaches include: restrictions in the
number of CIGs that can be combined, necessity of all solutions to be available in
a knowledge base, and decidability of reasoning mechanisms. In the approaches
that require hard-coded solutions, if a conflict that is not accounted for in the
knowledge base appears, the reasoning component will not be able to provide
a response. Also worth mentioning is that current approaches do not provide
support for ranking sets of guideline recommendations that are consistent.
3 An Architecture for CIG Management with
CIG Interaction Detection and Resolution
The present work not only aims to provide recommendations to support medical
decision-making but also to represent automatically the conflicts and interac-
tions that can happen when merging CIGs. In this work we focus on drug-drug
interactions and propose a system capable of automatically identifying recom-
mendation (drug) interactions using existing terminology services, namely the
RxNorm API [7]. Once interactions are identified, we provide alternative mea-
sures, i.e., alternative drugs to the ones recommended that would not cause any
conflict, through a mitigation function. This function calculates the solutions
for the identified conflicts using different mitigation principles such as similarity
between drugs or user preferences. The architecture is shown in Figure 1. This
architecture is a three-level solution that encompasses the following stages for
the CIG deployment: representation of CPGs in CIGs, identification of recom-
mendation interactions and provision of recommendation alternatives in case
that some recommendations, when applied together, are adverse. The following
sections explains the architecture that integrates these three levels.
3.1 Representation of CPGs in CIGs
The work described herein uses the CompGuide ontology to represent CPGs
in the form of a task network. The CompGuide ontology [10] contains differ-
ent types of clinical tasks such as Question, Action, Decision, End, Plan and
provides different types of clinical constraints expressed in the form of con-
ditions on the patient’s state, such as TriggerConditions, PreConditions and
Outcomes. Through the utilisation of object properties to connect instances of
the sub-classes of the clinical tasks, it is possible to define the relative order
between tasks. In the Compguide ontology, it is possible to define sequential
tasks, parallel tasks , and alternative tasks. Moreover, it provides a model of
temporal representation [11] that aims to represent the temporal constraints
placed on clinical tasks. This model represents temporal constructors on the
execution of tasks such as Durations, Repetitions, Periodicities, Waiting Times
and Repetition Conditions and temporal constraints about the state of a patient.
To acquire and represent CPGs we use the CompGuide plugin which provides
information step-by-step on how to fill the data for the guideline entries [4].
This plugin performs the role of managing the creation and editing of CIGs.
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Figure 1: Architecture of CompGuide system
The output of guideline encoding is a will CIG that will be saved in the
Guideline Repository. This component is responsible for keeping different CIGs
defined according to the CompGuide ontology. The Guideline Handler is re-
sponsible for managing the access to CIG recommendations in the Guideline
Repository, providing the clinical tasks and constraints placed on the tasks to
the Guideline Execution Engine.
3.2 Identification of Recommendation Interactions
The Guideline Handler provides clinical task details to the Guideline Execu-
tion Engine in order to produce recommendations. This component provides
information about temporal constraints on the execution of the clinical tasks.
Using this information, the Guideline Execution Engine produces task enact-
ment times, and by using RxNorm Interaction API, it determines if drug-drug
interactions exist. As before-mentioned, the clinical tasks are defined, in the
CompGuide ontology, by a set of subclasses. One of these subclasses is Action,
in which it is possible to define a collection of drugs that require to be pre-
scribed. The Action class has several subtypes of actions, namely exams, pro-
cedures, medication recommendations and simple recommendations [11]. The
Recommendation medication provides a set of drugs that can be prescribed and
is used by Guideline Execution Engine to determine drug-drug interactions. By
using the RxNorm interaction API, it is possible to determine drug-drug inter-
actions, without the need to manually define drug interactions in the knowledge
base. Its interaction API [7] uses two data sources, ONCHigh and DrugBank
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and provide information such as source name, severity and description of the
interaction. Thus, the Guideline Execution Engine processes all the clinical
tasks that are being executed, retrieves all drugs and for each pair of drugs
calls the RxNorm Interaction API to obtain the severity and description of the
interaction.
3.3 Generating Alternative Recommendations
After processing all drug-drug interactions between concurrently executed clin-
ical recommendations, the alternative measures are evaluated by the system.
If an adverse drug event exists, the systems automatically try to find alterna-
tive recommendations to resolve the conflict. Through a mitigation function,
the system determines which alternative recommendations are advised. This
function encompasses a set of steps that include the following:
• Step 1: The system tries to find if it is possible to get alternative rec-
ommendations, i.e., alternative drugs, in the guidelines. For each specific
guideline recommending a drug, the system calculates if an alternative rec-
ommendation exists within the guideline. If it is not possible to retrieve
the alternative recommendation, the system moves to step 2;
• Step 2: Using the RxNorm API, the system tries to find conflict-free alter-
native drugs. The system provides these alternative drugs by determining
the set of alternatives that have the high similarity score concerning the
given drugs. The RxNorm API provides the similarity score. If there are
no alternative drugs the system moves to step 3;
• Step 3: The system evaluates all possible solutions using Multiple-criteria
Decision Analysis (MCDA). Since drug-drug interactions are yielding mul-
tiple solutions with conflicting objectives, it is useful to score the solutions.
The patient and physician score all possible solutions, so this is a shared
patient-clinician evaluation supported by the system.
In step 1, the system tries to resolve the conflicts by analysing within the
guideline the different task alternatives. In this particular case, if alternative
tasks (recommending alternative drugs) exist in the guideline, the system tries
to retrieve them. Then, it gets all the recommended drugs of the alterna-
tive tasks and tries to find if drug-drug interactions exist in them, by calling
RxNorm Interaction API for each pairwise drugs of the task. In step 2, a rank-
ing of alternative drugs is produced based on the similarity score provided by
the RxNorm API. The similarity score between drugs is a score that determines
the similarity between drugs. Thus, the system calls the RxNorm API to get
alternative drugs for the given conflicted drugs and calculates the highest sim-
ilarity score for the alternative drugs and for each alternative with the higher
score it tries to encounter conflict-free drug. If there is a conflict, the system
finds the next alternative with the higher score, if there is no conflict, it stores
the alternative in the knowledge base. Table 1 presents the MCDA approach for
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step 3. This approach uses a value measurement model where for each criterion
the patient assigns a score. The objective of this model is constructing and
comparing numerical scores (overall value) to identify the degree to which one
decision alternative is preferred over another. Each alternative to be scored is
a combination of drugs.The system automatically defines the criteria by which
decision-makers should orient. Thus, when an adverse drug event occurs, and
the system moves to step 3, the criteria established are: severity of disease for
which drugs are advised, adverse drug-drug interactions and expected outcomes
for the drug application. The criteria are defined on the basis of some types of
health care decisions that are implemented in projects such as EMAs Benefit-
Risk Methodology Project [12] and shared patient-clinician decision [3]. The
total score for each alternative is obtained by multiplying a numerical score for
each option on a given criterion by the relative weight for the criterion and





Sn ∗WeightCn , (1)
where n is the number of solutions to be scored, Sn a score of a specific solution
and WeightCn relative weight for a specific criterion.
The relative weight for the criterion is a value defined by the healthcare
professional. This value is requested before starting the evaluation of the so-
lutions. After getting the user scores, the system determines the total score of
each solution by using the aforementioned equation. Thus, the total scores of
each solution are made available through the Personal Assistant Web App and
Healthcare assistant Mobile App, presenting the selected solution. Moreover,
after processing the constraints of clinical tasks, determining the interactions
between drugs and their alternatives, the clinical recommendations are made
available in before-mentioned assistants. In this assistants, it is possible to vi-
sualise the clinical recommendations that currently are being applied to the
patient, in a calendar and timeline view. Thus, each clinical recommendation
can have a set of drugs or alternative solutions that were previously evaluated
and scored by decision makers.
Table 1: Assessment of all possible solutions. The symbol C indicates a certain






α1 S1C1 ... S1Cn f (1) =
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n=1 S
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αn SnCn ... SnCn f (n) =
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n=1 S
n ∗WeightCn , (3)
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4 Case Example
This section describes how CompGuide processes the interactions between drugs
given a case test example. For this purpose, we used two CIGs based on the
NCCN Clinical Practice Guideline for Prostate Cancer [9] and the IDF Clinical
Practice Recommendations for managing Type 2 Diabetes [1]. These guidelines
were a comprehensive case study since it was possible to test several aspects of
the deployment of CIGs . However, in this section, we only address the conflicts
between recommendations from many guidelines and provision of alternative
recommendations using step 2 described in section 3.2.
For demonstration purposes, we will consider two recommendations from
the mentioned guidelines. The first one, named recommendation A belongs to
the guideline for managing Type 2 Diabetes: ”Apply insulin 0.2 units/kg and
titrate once weekly at one unit each time during six months to achieve a target
fasting blood glucose between 3.9 and 7.2 mmol/L (70 and 130 mg/dL)”. The
second recommendation, named recommendation B belongs to the guideline for
prostate cancer: ”Apply goserelin, leuprolide, histrelin 180 mg/m2 or Triptorelin
100mg/m2 as part of Androgen Deprivation Therapy”.
Recommendation A has the action apply insulin, a periodicity value of 1
with a temporal unit of week, a duration value of six, the respective temporal
unit of month and medication recommendation insulin. In this case, starting on
the 18th of July of 2018 the system will create one event for each week with a
duration of one day, during 6 months. The expected conclusion of this task will
be on the 18th of January of 2019. As for recommendation B, the action to apply
goserelin, leuprolide, histrelin or triptorelin can be identified, with a duration
value of 1 and temporal unit of day, starting and finishing on the 18th of July
of 2018. The recommendation medications are goserelin, leuprolide, histrelin
and Triptorelin. The application tries to provide alternative drugs to address
the identified conflicts, by calling RxNorm API and will provide alternative
medicines according to step 2, as described in section 3.2. Also, in this step the
system calculates a ranking of conflict-free alternative drugs, using the similarity
score provided by RxNorm API. The ranking of alternative drugs is calculated
by comparing similarity scores and sorting in descending order the medicines
according to this similarity values. For the alternative drug (drug provided by
RxNorm) with a higher score, the system determines if it is conflict-free over
the prescribed drugs. If there is a conflict, the system finds the next alternative
with the higher similarity score, if there is no conflict, it stores the alternative
in the database and displays the alternative drug as the selected solution.
In the work described herein, we provide a system that automatically iden-
tifies conflicts and interactions between drugs for many guidelines. Comparing
with the works of Jafarpour et al. (2013) [5], Wilk et al. (2017) [13] and Lpez-
Valverd et al. (2013) [8], where conflicts are defined as constraints in the knowl-
edge base having to be manually specified, CompGuide uses existing terminology
services that aggregate different drug sources such as ONCHigh and DrugBank.
Thus, through the reuse and integration of existing terminology services such
as RxNorm, it is possible to identify conflicts and interactions automatically,
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without the need to manually define them in the knowledge base. Therefore,
using existing terminology services and resorting to external knowledge sources
is one of the possible solutions for the limitation mentioned above.Another so-
lution concerns the use of meta-rules such as those used by the TM4I model.
Meta-rules can be reused since they can be applied to many CIGs, and conflicts
do not need to be manually identified for each guideline, because they can be
automatically derived from the guideline representation. However, the bottle-
neck will be in converting guidelines to computer-interpretable rules. Besides,
these systems do not consider aspects such as decision-making. In most cases,
there are several alternatives that can lead to conflicting objectives by the deci-
sion makers. In other cases, it is necessary to decide which recommendation we
want to choose, or which recommendation, in the case at hand, is less adverse.
For this specific case, we provide an MCDA approach that allows to evaluate
all possible solutions based on conflicting criteria.
5 Conclusions and Future Work
The application of multiple clinical protocols individually can result in complex
multiple drug regimens (polypharmacy) with the potential for harmful combina-
tions of drugs. Some of the studied approaches are unable to detect the conflicts
for combinations of protocols automatically. Other approaches cannot propose
alternative measures that would resolve the conflicts. Other CIG models require
all the possible conflicts and their solutions to be available in a knowledge base.
Moreover, they cannot lead with cases where decision makers have conflicting
solutions or cannot decide on the best treatment alternatives.
As a means to solve these issues, we provide a multiple criteria decision-
making approach for not only assessing the benefit-risk of applying the recom-
mendations but also getting patient preferences on best treatment alternatives.
This allows to evaluate all possible solutions and to specify different criteria to
solve conflicts with medical recommendations, beyond the simple comparison of
drug interactions. We also offer a system that allows to combine the knowledge
of several guidelines and to identify drug interactions and conflicts among many
recommendations automatically. Comparing with some of the studied systems,
the CompGuide has an additional advantage since it presents a method to auto-
matically identify drug-drug conflicts among many recommendations, without
a necessity of manually define them in the knowledge base. Also, when deci-
sion makers have conflicting solutions and cannot decide on the best treatment
alternatives, the CompGuide presents an approach that allows to evaluate all
possible solutions and to specify different criteria to solve conflicts with medical
recommendations. As future work, we intend to make a proper assessment of
the fitness of the system for CIG deployment, by performing a study involv-
ing physicians interacting with the system in the clinical environment. In this
ways, it is possible to analyse if the system meets the requirements of health
professionals and if it is user-friendly.
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